Energy recovery director Hanstveit sells $534k in stock

Director Arve Hanstveit sold $534,399 of Energy Recovery (ERII) stock in two trades (38,418 shares at $10.71 on Mar 5 and 11,582 shares at $10.615 on Mar 6), leaving him with 575,220 shares. Q4 2025 EPS was $0.53 vs $0.64 consensus (miss by 17.19%), revenue was $66.9M vs $82.59M expected (miss by 19%), and 2026 revenue guidance of $115M–$140M sits well below the $165M analyst average; shares have fallen ~23% over six months. Freedom Capital cut its price target to $13 from $18.20 while retaining a Buy, and the company announced it will exit its carbon dioxide retail grocery business.

Analysis

The market is treating the company like a short-duration discretionary engineering vendor rather than a backlog-driven capital-equipment supplier; that pricing disconnect amplifies near-term downside from lumpiness but also creates optionality if a few megaproject milestones slip back on schedule. Management’s move to refocus away from peripheral retail CO2 activities is a de-risking step that should lower SG&A volatility and improve free-cash-flow conversion over multiple quarters, but the benefits will be earned incrementally and are unlikely to offset a single large project deferral in the same reporting period.

Insider liquidity and analyst target compression have amplified volatility and reduced natural buyers, creating windows where event-driven flows (earnings, tender awards) can produce outsized moves; this makes option structures more attractive than outright equity for controlling downside while retaining asymmetric upside. On the other side, the company remains exposed to contractor and sovereign capex cycles — a macro downturn or oil/gas capex pullback would quickly propagate into order deferrals, making the path to consensus revenue a multi-quarter tracking exercise rather than a single catalyst.

Net-net: the stock behaves like a multi-modal distribution — frequent short-term disappointments but materially positive outcomes if a handful of large projects execute or if margin recovery from cost rationalization accelerates. Positioning should therefore be event-aware and size-aware: small directional equity for a multi-quarter rebound, option-based asymmetric exposure to capture recovery without risking balance-sheet-sized losses, and a clear hedge if you’re front-running any near-term guidance release or tender decision.

Key Decisions for Investors

• Long ERII equity (tactical, 1–3% portfolio) — enter on a 5–15% post-earnings retracement window within the next 2–6 weeks. Target +50–70% in 12–18 months if project roll-ins and margin cleanup materialize; hard stop at -30% to cap tail loss from a large project deferral.
• Buy ERII long-dated calls (asymmetric play) — purchase 12–18 month calls (e.g., Jan 2027–Jan 2028 expiries) sized at 0.5–1% portfolio. Max loss = premium; aim for 3x+ payoff if the company converts backlog, wins tenders, or shows sequential margin expansion over two quarters.
• Pair trade: long ERII / short XLI (equal-dollar) — horizon 6–12 months to isolate company-specific operational recovery from broader industrial cyclicality. Expect positive returns if ERII’s backlog converts while industrials remain range-bound; unwind if macro industrial demand re-accelerates and ERII continues to miss execution.
• Event hedge: buy a 3-month bear put spread on ERII before the next guidance/quarterly report — defined-cost hedge sized to cover equity downside during the event. Entry if insider/activity or analyst revisions spike implied volatility; target 2:1 payoff vs. premium if guidance deteriorates.